论文部分内容阅读
目的:探讨软组织肉瘤中增殖细胞核抗原Ki-67、EGFR和PDGFR表达状况对判断预后的临床价值。方法:免疫组化法检测60例软组织肉瘤患者瘤体组织Ki-67、EGFR和PDGFR的表达水平,结合短期随访观察Ki-67、EGFR和PDG-FR不同表达的患者总生存率和复发率的差异。结果:Ki-67阴性表达患者第1年和第2年总生存率分别为100.0%和95.5%,均高于阳性表达患者的83.9%和76.0%;Ki-67阴性表达患者第1年和第2年复发率分别为6.9%和8.3%,高于阳性表达患者的22.6%和48.0%。EGFR与Ki-67均为阳性表达与均为阴性表达的患者,第1、2年的总生存率差异无统计学意义,P>0.05;PDGFR与Ki-67均为阳性表达与均为阴性表达的患者,第1、2年的总生存率差异无统计学意义,P>0.05。结论:增殖细胞核抗原Ki-67在软组织肉瘤中阳性表达提示预后不良,增加EGFR、PDGFR与Ki-67进行双指标检测并未提高预测的敏感性。
Objective: To investigate the clinical value of the expression of proliferating cell nuclear antigen Ki-67, EGFR and PDGFR in soft tissue sarcoma in predicting prognosis. Methods: The expressions of Ki-67, EGFR and PDGFR in 60 cases of soft tissue sarcoma were detected by immunohistochemistry. The survival rates and recurrence rates of Ki-67, EGFR and PDG-FR were observed with short-term follow-up difference. Results: The overall survival rates at 1 year and 2 years in patients with negative Ki-67 expression were 100.0% and 95.5%, respectively, which were higher than 83.9% and 76.0% in patients with positive Ki-67 expression. The 2-year recurrence rates were 6.9% and 8.3%, respectively, higher than 22.6% and 48.0% of patients with positive expression. There was no significant difference in the overall survival rates between the first and second years (P> 0.05). Both PDGFR and Ki-67 were positive and negative for both EGFR and Ki-67 Of patients, the first and second year of the overall survival difference was not statistically significant, P> 0.05. CONCLUSION: The positive expression of proliferating cell nuclear antigen Ki-67 in soft tissue sarcoma indicates poor prognosis. Increasing the double-index detection of EGFR, PDGFR and Ki-67 did not improve the predictive sensitivity.